Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 5/20 | 0.36 |
| ▸ | GJB2 | P29033 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13772551 | 1.00 | TNF (0.40) | TNFMAPK1CD209LGALS8GJB2 | |
| SCHEMBL13772552 | 1.00 | TNF (0.40) | TNFMAPK1CD209LGALS8GJB2 | |
| SCHEMBL15267653 | 1.00 | TNF (0.40) | TNFMAPK1CD209LGALS8GJB2 | |
| SCHEMBL17794462 | 1.00 | TNF (0.40) | TNFMAPK1CD209LGALS8GJB2 | |
| SCHEMBL15267655 | 1.00 | TNF (0.40) | TNFMAPK1CD209LGALS8GJB2 | |
| SCHEMBL13806499 | 0.91 | TNF (0.40) | TNFMAPK1CD209LGALS8GJB2 | |
| SCHEMBL14817730 | 0.91 | TNF (0.40) | TNFMAPK1CD209LGALS8GJB2 | |
| SCHEMBL15296514 | 0.91 | TNF (0.40) | TNFMAPK1CD209LGALS8GJB2 | |
| SCHEMBL14900306 | 0.91 | TNF (0.40) | TNFMAPK1CD209LGALS8GJB2 | |
| SCHEMBL15296532 | 0.85 | TNF (0.35) | TNFMAPK1LGALS8GJB2LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152653-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | MEIJI SEIKA PHARMA CO LTD (JP) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152653-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | ATP6V1B1, REN, NRDC | TNF 456/4885MAPK1 1801/4885CD209 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.